Background {#Sec1}
==========

Reduced-intensity conditioning (RIC) regimens currently account for approximately 40--45% of all allogeneic transplants performed in the USA \[[@CR1]\]. These lower-intensity regimens rely more heavily on the graft-versus-tumor effects (exerted by the donor effector cells) to eradicate the residual disease in transplant recipients. RIC regimens are generally associated with a lower risk of procedure-related morbidity and non-relapse mortality (NRM) rates, thereby extending the option of allogeneic hematopoietic cell transplantation (allo-HCT) to patients with advanced age and/or significant medical comorbidities.

Considering the median age at diagnosis of patients with non-Hodgkin lymphomas (NHL) (\~66 years), it is not surprising that RIC regimens now account for the majority of allo-HCTs performed for lymphomas in the USA \[[@CR1]\]. However, the risk of disease relapse tends to be generally higher following RIC regimens compared to myeloablative allo-HCT in NHL \[[@CR2], [@CR3]\]. Identification of RIC approaches with the best risk/benefit ratio (NRM vs. relapse rate) in NHL remains an unmet medical need. Disease-specific RIC regimens, incorporating targeted therapies, can potentially provide improved peri-transplantation disease control, without increasing the rates of transplant-related morbidity and mortality. RIC regimens containing rituximab, an antiCD20 antibody with antineoplastic activity, have been employed in patients with B cell NHL \[[@CR4]--[@CR8]\]. Several single-institution studies incorporating rituximab in RIC regimens for B cell NHL have reported excellent disease control, with low rates of toxicity and severe graft-versus-host disease (GVHD) \[[@CR4], [@CR7]\]. However, large, multicenter studies comparing outcomes of RIC regimens incorporating rituximab, against those without rituximab in B cell NHL, have not been performed. We report here a registry analysis, comparing outcomes of rituximab-containing RIC (R-RIC) regimens versus non-rituximab containing RIC (nonR-RIC) regimens in B cell NHL.

Methods {#Sec2}
=======

Data sources {#Sec3}
------------

The CIBMTR is a working group of more than 500 transplantation centers worldwide that contribute detailed data on HCT to a statistical center at the Medical College of Wisconsin (MCW). Participating centers are required to report all transplantations consecutively, and compliance is monitored by on-site audits. Computerized checks for discrepancies, physicians' review of submitted data, and on-site audits of participating centers ensure data quality. Observational studies conducted by the CIBMTR are performed in compliance with all applicable federal regulations pertaining to the protection of human research participants. The MCW and National Marrow Donor Program, Institutional Review Boards approved this study.

The CIBMTR collects data at two levels: Transplant Essential Data (TED) and Comprehensive Report Form (CRF) data. TED-data includes disease type, age, gender, pre-HCT disease stage and chemotherapy-responsiveness, date of diagnosis, graft type, conditioning regimen, post-transplant disease progression and survival, development of a new malignancy, and cause of death. All CIBMTR centers contribute TED-data. More detailed disease and pre- and post-transplant clinical information is collected on a subset of registered patients selected for CRF data by a weighted randomization scheme. TED- and CRF-level data are collected pre-transplant, 100-days and 6 months post-HCT, and annually thereafter or until death. Data for the current analysis were retrieved from CIBMTR (TED and CRF) report forms.

Patients {#Sec4}
--------

Included in this analysis are adult (≥18 years) patients with B cell NHL, undergoing their first RIC or non-myeloablative conditioning (NMA) allo-HCT between 2008 and 2014. Eligible histologies included diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). Eligible donors including either HLA-identical sibling donors or unrelated donors (URD) matched at the allele-level at HLA-A, HLA-B, HLA-C and HLA-DRB1. Peripheral blood or bone marrow was permitted graft-source. GVHD prophylaxis was limited to calcineurin inhibitor (CNI)-based approaches. Patients receiving ex vivo graft manipulation (T cell depleted = 8 or CD34 selected grafts = 28) were not included. Use of antithymocyte globulin (ATG) during allo-HCT was not considered as an exclusion. Since alemtuzumab was used infrequently in patients receiving rituximab-based RIC (*n* = 1), these cases were not included. Radioimmunotherapy-based RIC regimens were excluded (*n* = 26).

Definitions {#Sec5}
-----------

The intensity of conditioning regimens was defined using consensus criteria \[[@CR9]\]. Complete remission (CR) to last line of therapy before allo-HCT on CIBMTR forms is defined as complete resolution of all known areas of disease on radiographic assessments, while partial remission (PR) is defined as ≥50% reduction in the greatest diameter of all sites of known disease and no new sites of disease \[[@CR10]\]. The resistant disease is defined as \<50% reduction in the diameter of all disease sites, or development of new disease sites. Disease risk index (DRI) was defined as reported previously \[[@CR11]\].

Study endpoints {#Sec6}
---------------

The primary endpoint was overall survival (OS); death from any cause was considered an event, and surviving patients were censored at last contact. NRM was defined as death without evidence of lymphoma progression/relapse; relapse was considered a competing risk. Progression/relapse was defined as progressive lymphoma after HCT or lymphoma recurrence after a CR; NRM was considered a competing risk. For progression-free survival (PFS), a patient was considered a treatment failure at the time of progression/relapse or death from any cause. Patients alive without evidence of disease relapse or progression were censored at last follow-up. Acute GVHD \[[@CR12]\] and chronic GVHD \[[@CR13]\] were graded using standard criteria. Neutrophil recovery was defined as the first of three successive days with absolute neutrophil count (ANC) ≥500/μL after post-transplantation nadir. Platelet recovery was defined as achieving platelet counts ≥20,000/μL for at least 3 days, unsupported by transfusion. For neutrophil and platelet recovery, death without the event was considered a competing risk.

Statistical analysis {#Sec7}
--------------------

The R-RIC cohort was compared against the nonR-RIC cohort. Probabilities of PFS and OS were calculated as described previously \[[@CR14]\]. Cumulative incidence of NRM, lymphoma progression/relapse, and hematopoietic recovery were calculated to accommodate for competing risks \[[@CR15]\]. Associations among patient-, disease-, and transplantation-related variables and outcomes of interest were evaluated using Cox proportional hazards regression. A stepwise model building approach was used to identify covariates that influenced outcomes. Covariates with a *p* \< 0.05 were considered statistically significant. The proportional hazards assumption for Cox regression was tested by adding a time-dependent covariate for each risk factor and each outcome. Interactions between the main effect and significant covariates were examined (in particular disease histology, GVHD prophylaxis regimen, and remission status at HCT), and none were found. Results are expressed as relative risks (RR). The center effect was examined using the random effect score test \[[@CR16]\] for OS, PFS, relapse, and NRM. The marginal Cox proportional hazards model was used to account for the center effect on chronic GVHD, NRM, relapse, PFS, and OS \[[@CR17]\]. Generalized linear mixed model with the logit link function was used to account for the center effect on acute GVHD II-IV and III-IV. The variables considered in multivariate analysis are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC).

Results {#Sec8}
=======

Baseline characteristics {#Sec9}
------------------------

The patient population was divided into two groups; 379 patients receiving rituximab as part of RIC regimens were included in the R-RIC group, while 1022 patients not receiving rituximab with conditioning constituted the nonR-RIC cohort. The baseline patient-, disease-, and transplantation-related characteristics are shown in Table [1](#Tab1){ref-type="table"}. There was no significant difference between the two groups in terms of patient age, gender, race, Karnofsky performance score (KPS), HCT-comorbidity index (HCT-CI), interval between diagnosis and allo-HCT, median lines of prior therapy, remission status at HCT, total body irradiation (TBI) use in conditioning, donor type, donor-recipient sex match, and donor-recipient CMV serostatus. DLBCL was the most common histology in the nonR-RIC group (44%) while FL was the most common histology (37%) in the R-RIC group (*p* \< 0.001). The proportion of patients with intermediate DRI (50 vs. 40%; *p* = 0.03) and history of a prior autologous HCT (43 vs. 26%; *p* \< 0.001) was higher in the nonR-RIC cohort. Fludarabine/busulfan (Flu/Bu) ± total body irradiation (TBI) was the most common conditioning in the nonR-RIC group (35%) while fludarabine/cyclophosphamide (Flu/Cy) ± TBI in the R-RIC group (54%). CNI ± methotrexate-based GVHD prophylaxis was more common in the R-RIC group (55 vs 38%; *p* \< 0.001). The graft source was mainly peripheral blood in both groups (95% \[*n* = 970) vs. 98% \[*n* = 371\] in the nonR-RIC and R-RIC groups, respectively). Median follow-up of survivors was 37 months (range, 2--79 months) in the nonR-RIC group and 47 months (range, 6--89 months) in the R-RIC group.Table 1Baseline patient characteristics of patients with NHL reported to the CIBMTR from 2008 to 2014VariableNon-rituximab-RIC\
*N* = 1022Rituximab-containing RIC\
*N* = 379*p* valueAge at HCT, years Median (range)57 (18--74)56 (28--74)0.32 \>65142 (14)45 (12)0.07Male gender667 (65)248 (65)0.95Race0.55 Caucasian918 (90)359 (95) African American24 (2)8 (2) Others17 (2)10 (3) Missing63 (6)2 (\<1)Karnofsky performance score ≥90622 (61)235 (62)0.24HCT-CI0.58 0331 (32)141 (37) 1--2301 (29)115 (30) ≥3326 (32)120 (32) Missing64 (6)3 (\<1)Histology\<0.001 Follicular lymphoma268 (26)142 (37) Diffuse large B cell lymphoma452 (44)124 (33) Mantle cell lymphoma274 (27)106 (28) Marginal zone lymphoma28 (3)7 (2)Interval from diagnosis to HCT, months0.73 Median (range)36 (2-386)39 (3-310)Median lines of therapy before HCT3 (1-9)3 (1-8)0.54Remission status at HCT0.19 Complete remission459 (45)147 (39) Partial remission421 (41)169 (45) Chemorefractory125 (12)59 (16) Untreated8 (\<1)2 (\<1) Unknown9 (\<1)2 (\<1)Disease risk index at HCT0.003 Low405 (40)184 (49) Intermediate509 (50)151 (40) High99 (10)42 (11) Missing9 (\<1)2 (\<1)History of prior autologous HCT436 (43)99 (26)\<0.001Conditioning regimen\<0.001 Flu/Bu ± TBI360 (35)21 (5) Flu/Cy ± TBI156 (15)207 (54) Flu/Mel ± TBI271 (27)55 (15) 2 Gy TBI ± Flu196 (19)40 (11) BEAM or similar39 (4)56 (15)TBI in conditioning265 (26)90 (24)0.40ATG in conditioning191 (19)75 (20)0.64Graft source0.02 Bone marrow52 (5)8 (2) Peripheral blood970 (95)371 (98)Donor type0.10 HLA-identical sibling565 (55)191 (50) URD 8/8457 (45)188 (50)Donor-recipient sex match66 (36)227 (46)0.62 Male-male434 (42)168 (44) Male-female222 (22)89 (23) Female-male233 (23)80 (21) Female-female133 (13)42 (11)Donor/recipient CMV status0.14 Both negative305 (30)112 (30) Either donor/recipient+711 (70)259 (68) Missing6 (\<1)8 (2)Graft-versus-host disease prophylaxis\<0.001 Calcineurin inhibitor + MTX ± others^a^\
(except MMF and sirolimus)392 (38)207 (55) Calcineurin inhibitor + MMF ± others^a^\
(except sirolimus)402 (39)95 (25) Calcineurin inhibitor + sirolimus ± others^a^200 (20)75 (20) Calcineurin inhibitor alone28 (3)2 (\<1)Median follow-up of survivors (range), months37 (2--79)47 (6--89)Number of centers that reported only nonR-RIC cases = 76, R-RIC cases = 3, and both (nonR-RIC and R-RIC) cases = 35*Abbreviations*: *ATG* antithymocyte globulin, *Bu* busulfan, *CMV* cytomegalovirus, *Cy* cyclophosphamide, *Flu* fludarabine, *HCT* hematopoietic cell transplantation, *HCT*-*CI* HCT-comorbidity index, *Mel* melphalan, *MMF* mycophenolate mofetil, *MTX* methotrexate, *TBI* total body irradiation, *RIC* reduced-intensity conditioning^a^For details, refer to Additional file [1](#MOESM1){ref-type="media"}: Table S8

Hematopoietic recovery {#Sec10}
----------------------

The cumulative incidence of neutrophil recovery at day 28 was 97% (95%CI 96--98) in the nonR-RIC group compared to 98% (95%CI 96--99) in the R-RIC group (*p* = 0.51). The day-28 cumulative incidence of platelet recovery in similar order was 90 vs. 90% (*p* = 0.66; Table [2](#Tab2){ref-type="table"}).Table 2Univariate analysisNon-rituximab-RIC\
*N* = 1022Rituximab-containing RIC\
*N* = 379OutcomesN evalProb (95%CI)N evalProb (95%CI)*p* valueANC recovery \>500/uL1013379 28 days97 (96--98)%98 (96--99)%0.51 100 days99 (98--99)%99 (97--100)%0.99Platelet recovery ≥ 20/uL986378 28 days90 (88--92)%90 (87--93)%0.66 100 days96 (94--97)%96 (93--97)%0.79Acute GVHD (II IV)1004377 180 days37 (34--40)%43 (38--48)%0.03Acute GVHD (III IV)1004377 180 days13 (11--16)%16 (12--19)%0.29Chronic GVHD982369 1 year44 (41--48)%41 (36--47)%0.32 2 years53 (50--57)%53 (47--58)%0.79NRM988367 1 year14 (12--16)%13 (10--17)%0.78 3 years21 (18--24)%20 (16--24)%0.68Relapse/progression988367 1 year26 (23--29)%19 (15--23)%0.004 3 years32 (29--35)%24 (20--29)%0.005PFS988367 1 year60 (57--63)%68 (63--72)%0.007 3 years47 (44--50)%56 (51--61)%0.005Mortality (inverse of OS)1022379 1 year70 (67--73)%76 (71--80)%0.04 3 years56 (53--59)%64 (59--68)%0.01Probabilities of neutrophil and platelet recovery, platelet recovery, acute GVHD, chronic GVHD, treatment-related mortality, and progression/relapse were calculated using the cumulative incidence estimate. Progression-free survival and overall survival was calculated using the Kaplan-Meier product limit estimate*Abbreviations*: *ANC* absolute neutrophil count, *GVHD* graft-versus-host disease, *PROB* probability, *CI* confidence interval, *N eval* number evaluable, *NRM* non-relapse mortality, *PFS* progression free survival, *RIC* reduced-intensity conditioning, *OS* overall survival

Acute and chronic GVHD {#Sec11}
----------------------

On univariate analysis, the cumulative incidence of grade II--IV acute GVHD at day 180 (Table [2](#Tab2){ref-type="table"}) in the nonR-RIC cohort was 37% (95%CI 34--40), compared to 43% (95%CI 38--48) in the R-RIC group (*p* = 0.03). The corresponding rates of grades III--IV acute GVHD were 13% (95%CI 11--16) vs. 16% (95%CI 12--19) in the nonR-RIC and R-RIC groups, respectively, (*p* = 0.29). There was a significant center effect for grade II--IV acute GVHD (*p* = 0.004) and grade III--IV acute GVHD (*p* = 0.01). On multivariate analysis (Table [3](#Tab3){ref-type="table"}), after adjusting for the center effect, R-RIC was not associated with a higher risk of grade II--IV (RR = 1.14, 95%CI = 0.83--1.56, *p* = 0.43) or grade III--IV (RR = 1.16, 95%CI = 0.72--1.89, *p* = 0.54) acute GVHD, relative to the nonR-RIC cohort. Grade II--IV acute GVHD was associated with a significantly high NRM (RR = 2.88, *p* \< 0.0001), inferior PFS (RR = 1.6, *p* \< 0.0001), and OS (RR = 1.93, *p* \< 0.0001) in our study.Table 3Multivariate analysis resultsNumberRelative risk95%CI\
lower limit95%CI\
upper limit*p* valueAcute GVHD (grades 2--4)^a^ Non-rituximab RIC100410.43 Rituximab-containing RIC3771.140.831.56Acute GVHD (grades 3--4)^a^ Non-rituximab RIC100410.54 Rituximab-containing RIC3771.160.721.89Chronic GVHD Non-rituximab RIC98210.22 Rituximab-containing RIC3691.150.921.46Non-relapse mortality Non-rituximab RIC98810.51 Rituximab-containing RIC3670.900.671.22Progression/relapse Non-rituximab RIC98810.055 Rituximab-containing RIC3670.790.631.01PFS Non-rituximab RIC98810.006 Rituximab-containing RIC3670.760.620.92Mortality Non-rituximab RIC102210.08 Rituximab-containing RIC3790.840.691.02*Abbreviations*: *GVHD* graft-versus-host disease, *CI* confidence interval, *RIC* reduced-intensity conditioning^a^Acute GVHD models used logistic regression

On univariate analysis, the cumulative incidence of chronic GVHD at 1 year (Table [2](#Tab2){ref-type="table"}) after nonR-RIC transplant was 44% (95%CI 41--48) compared to 41% (95%CI 36--47) in the R-RIC group (*p* = 0.32). There was significant center effect noted for chronic GVHD (*p* \< 0.0001). After adjusting for center effect, multivariate analysis (Table [3](#Tab3){ref-type="table"}) showed no significant difference in the risk of chronic GVHD in the recipients of R-RIC transplant, (RR = 1.15, 95%CI = 0.92--1.46, *p* = 0.22) relative to the nonR-RIC group (Fig. [1a](#Fig1){ref-type="fig"}).Fig. 1Adjusted transplantation outcomes of patients receiving R-RIC (interrupted lines) and nonR-RIC (solid line) regimens. **a** Cumulative incidence of chronic graft-versus-host-disease. **b** Cumulative incidence of non-relapse mortality. **c** Cumulative incidence of lymphoma relapse/progression. **d** Progression-free survival. **e** Overall survival

NRM and relapse {#Sec12}
---------------

The 1-year NRM rate in the nonR-RIC group was 14% (95%CI = 12--16) compared to 13% (95%CI = 10--17) in the R-RIC group (*p* = 0.78; Table [2](#Tab2){ref-type="table"}). There was a significant center effect noted for NRM (*p* = 0.005). On multivariate analysis, after adjusting for the center effect, R-RIC was not associated with a higher risk of NRM (RR = 0.90, 95%CI = 0.67--1.22, *p* = 0.51) (Fig. [1b](#Fig1){ref-type="fig"}). Other factors independently associated with the risk of NRM are shown in the Additional file [1](#MOESM1){ref-type="media"}: Table S2.

The cumulative incidence of relapse/progression at 3 years was 32% (95%CI = 29--35) and 24% (95%CI = 20--29) in the nonR-RIC and R-RIC groups, respectively, (*p* = 0.005; Table [2](#Tab2){ref-type="table"}). On multivariate analysis, the risk of relapse/progression was not significantly different between the two groups (RR = 0.79, 95%CI 0.63--1.01, *p* = 0.055) (Table [3](#Tab3){ref-type="table"}) (Fig. [1c](#Fig1){ref-type="fig"}). Other factors independently associated with the risk of relapse/progression are shown in the Additional file [1](#MOESM1){ref-type="media"}: Table S2.

Progression-free survival {#Sec13}
-------------------------

The 3-year PFS was significantly better in the R-RIC group (56%; 95%CI = 51--61) compared to the nonR-RIC group (47%; 95%CI = 44--50; *p* = 0.005; Table [2](#Tab2){ref-type="table"}). On multivariate analysis (Table [3](#Tab3){ref-type="table"}), relative to the nonR-RIC group, the R-RIC was associated with a significantly improved PFS (RR = 0.76, 95%CI = 0.62--0.92, *p* = 0.006) (Fig. [1d](#Fig1){ref-type="fig"}). Other factors independently associated with the PFS are shown in the Additional file [1](#MOESM1){ref-type="media"}: Table S2.

Overall survival {#Sec14}
----------------

The 3-year OS in the nonR-RIC and R-RIC groups was 56% (95%CI 53--59) and 64% (95%CI 59--68), respectively, *p* = 0.01 (Table [2](#Tab2){ref-type="table"}). There was a significant center effect noted for OS (*p* = 0.005). On multivariate analysis (Table [3](#Tab3){ref-type="table"}), after adjusting for the center effect, R-RIC was not associated with a significantly reduced risk of mortality (RR = 0.84, 95%CI = 0.69--1.02, *p* = 0.08) relative to nonR-RIC allo-HCT (Fig. [1e](#Fig1){ref-type="fig"}). Other factors independently associated with mortality risk are shown in the Additional file [1](#MOESM1){ref-type="media"}: Table S2.

Rituximab and disease histology {#Sec15}
-------------------------------

The interaction between the main effect (i.e., R-RIC vs. RIC) and disease histology (DLBCL, FL, MCL, and MZL) was checked for each outcome. It was not significant for grade II--IV acute GVHD (*p* = 0.18), grade III--IV acute GVHD (*p* = 0.64), chronic GVHD (*p* = 0.99), relapse (*p* = 0.96), NRM (*p* = 0.70), PFS (*p* = 0.84), and OS (*p* = 0.53) (For details of histology-specific multivariate models please refer to page 10 of Additional file [1](#MOESM1){ref-type="media"}: Tables S3-S5). The subset analysis for chemorefractory patients at the time of HCT is given in Additional file [1](#MOESM1){ref-type="media"}: Table S6.

Prior autologous transplant {#Sec16}
---------------------------

On multivariate analysis, independent of the type of RIC transplant (R or nonR), prior auto-HCT was associated with higher NRM (HR = 1.38, 95%CI 1.07--1.78, *p* = 0.01), inferior PFS (HR = 1.28, 95%CI 1.08--1.51, *p* = 0.004), and OS (HR = 1.22, 95%CI 1.02--1.46, *p* = 0.02) (Additional file [1](#MOESM1){ref-type="media"}: Table S2).

Pre-transplant rituximab {#Sec17}
------------------------

Among nonR-RIC and R-RIC groups, 149 and 89 cases on the CRF track had details of pre-transplant treatments available. Among this subset, 54% (*n* = 80) of nonR-RIC and 64% (*n* = 57) of R-RIC patients received rituximab as a part of last line therapy prior to transplantation (*p* = 0.12).

Causes of death {#Sec18}
---------------

At last follow-up, 43% (*n* = 444) of nonR-RIC and 37% (*n* = 139) of R-RIC transplant recipients had died (Additional file [1](#MOESM1){ref-type="media"}: Table-S6). The most common cause of death in both cohorts was recurrent/progressive lymphoma; 18% (*n* = 186) and 14% (*n* = 52) in the nonR-RIC and R-RIC groups, respectively. GVHD was the cause of death in 4% (*n* = 36) and 6% (*n* = 21) of recipients of nonR-RIC and R-RIC transplant, respectively. Infectious complications led to the death of 3% (*n* = 29) in nonR-RIC group and 3% (*n* = 13) in R-RIC group. Among the nonR-RIC and R-RIC groups, 157 and 89 cases on the CRF track had detailed post-transplant infectious disease data available. Among this subset, 26% (*n* = 41) of nonR-RIC and 20% (*n* = 18) of R-RIC patients had CMV reactivation (*p* = 0.20) and 1% (*n* = 2) of nonR-RIC and 2% (*n* = 2) of R-RIC patients had EBV reactivation (*p* = 0.60). Neither of the groups (R-RIC or nonR-RIC) had any HBV reactivation cases.

Subset analysis {#Sec19}
---------------

Among the 381 patients receiving Flu/Bu-based RIC, only 21 patients (5%) received rituximab-based conditioning. Results of multivariate analysis after excluding the patients receiving Flu/Bu-based conditioning are shown in Table [4](#Tab4){ref-type="table"}. These results were generally in line with multivariate analysis of overall study population and showed that relative to non-R-RIC group, the R-RIC group was associated with no difference in grade III--IV acute GVHD (RR = 0.89, 95%CI = 0.59--1.34, *p* = 0.58), chronic GVHD (RR = 1.07, 95%CI = 0.87--1.30, *p* = 0.51), NRM (RR = 0.79, 95%CI = 0.57--1.08, *p* = 0.14), or progression/relapse (RR = 0.82, 95%CI = 0.64--1.06, *p* = 0.13), and the R-RIC significantly improved PFS (RR = 0.002, 95%CI = 0.60--0.89, *p* = 0.002). However, unlike the overall multivariate model, this subgroup analysis showed a significantly reduced risk of mortality with R-RIC (RR = 0.76, 95%CI = 0.60--0.96, *p* = 0.02), relative to the nonR-RIC cohort.Table 4Multivariate analysis results (excluding Fludarabine/Busulfan-based conditioning regimens)NumberRelative risk95%CI\
lower limit95%CI\
upper limit*p* valueAcute GVHD (grades 3--4)^a^ Non-rituximab RIC64710.58 Rituximab-containing RIC3560.890.591.34Chronic GVHD Non-rituximab RIC63510.51 Rituximab-containing RIC3491.070..871.30Non-relapse mortality Non-rituximab RIC63810.14 Rituximab-containing RIC3460.790.571.08Progression/relapse Non-rituximab RIC63810.13 Rituximab-containing RIC3460.820.641.06PFS Non-rituximab RIC63810.002 Rituximab-containing RIC3460.730.600.89Mortality Non-rituximab RIC66210.02 Rituximab-containing RIC3580.760.600.96*Abbreviations*: *GVHD* graft-versus-host disease, *RIC* reduced-intensity conditioning^a^Acute GVHD models used logistic regression

Effect of cumulative rituximab dose in conditioning {#Sec20}
---------------------------------------------------

The cumulative (or total) dose of rituximab administered with allo-HCT conditioning varies significantly across different centers. To assess the impact of cumulative rituximab dose on HCT outcomes, we divided the R-RIC cohort patients into three groups based on the cumulative rituximab dose received during RIC---\<1000 mg/m^2^ (low; *n* = 214), 1000--1999 mg/m^2^ (intermediate; *n* = 113), and 2000--3375 mg/m^2^ (high; *n* = 47). On multivariate analysis (Table [5](#Tab5){ref-type="table"}), there was a reduced risk of chronic GVHD with the intermediate rituximab dose (RR = 0.64; 95%CI 0.46--0.90, *p* = 0.01) relative to the low dose rituximab group. High dose rituximab was associated with a reduced risk of NRM (RR = 0.18; 95%CI 0.04--0.75; *p* = 0.02) and overall mortality (RR = 0.43; 95%CI 0.21--0.90; *p* = 0.02), relative to the low dose group.Table 5Effect of cumulative rituximab dose on outcomesNumberRelative risk95%CI\
lower limit95%CI\
upper limit*p* valueOverall *p* valueChronic GVHDRituximab dose (mg/m^2^) \<100020810.03 1000--19991100.640.460.900.01 2000--3375460.920.621.360.67Non-relapse mortalityRituximab dose (mg/m^2^) \<100020810.06 1000--19991090.900.541.510.70 2000--3375450.180.040.750.02Progression/relapseRituximab dose (mg/m^2^) \<100020810.90 1000--19991091.010.631.610.97 2000--3375450.850.401.780.66PFSRituximab dose (mg/m^2^) \<100020810.21 1000--19991090.990.701.390.94 2000--3375450.560.301.070.08MortalityRituximab dose (mg/m^2^) \<100021410.052 1000--19991131.100.761.590.63 2000--3375470.430.210.900.02*Abbreviations*: *GVHD* graft-versus-host disease

Discussion {#Sec21}
==========

Prospective randomized studies comparing the outcomes of R-RIC and nonR-RIC in B cell NHL have not been performed. Here, we performed a registry analysis of B cell NHL patients receiving either rituximab-based or nonR-RIC regimens for allo-HCT, and make several important observations. First rates of hematopoietic recovery, relapse risk, and NRM were comparable between R-RIC and nonR-RIC allo-HCT. Second, R-RIC was not associated with a higher risk of either grade II--IV or grade III--IV acute GVHD and chronic GVHD. Third, there was a significantly superior PFS with R-RIC regimens, but in the overall study population, OS was similar. Finally, in the subset analysis, there was a survival benefit in favor of R-RIC regimens (after excluding Flu/Bu-based conditioning regimens) and a higher cumulative rituximab dose was associated with a reduced risk of NRM and improved survival.

In our study, R-RIC group was not associated with a higher risk of grade II--IV or grade III--IV acute GVHD compared to the nonR-RIC cohort. Our analysis also did not show any difference in the risk of chronic GVHD between the two groups. Previous studies using R-RIC have generally shown the rates of chronic GVHD at 1 year to be around 50--60% (Additional file [1](#MOESM1){ref-type="media"}: Table S7) \[[@CR4]--[@CR6], [@CR8]\]. Notably, some retrospective and one prospective phase II study using a prolonged rituximab administration schedule post allo-HCT have suggested reduced risk of chronic GVHD \[[@CR7], [@CR18], [@CR19]\]. However, a randomized trial did not show any reduction in chronic GVHD with post allo-HCT administration of rituximab. Of note, all patients in that study received myeloablative conditioning regimens \[[@CR20]\]. A recent single-center retrospective study comparing fludarabine, cyclophosphamide, and rituximab (FCR) RIC to Flu/Bu (without rituximab) \[[@CR21]\] reported lower rates of chronic GVHD and improved OS with R-RIC. However, in that study, all the patients in the FCR group received tacrolimus/methotrexate as GVHD prophylaxis, while those in the Flu/Bu group received tacrolimus/mycophenolate mofetil as GVHD prophylaxis that confounds the assessment of rituximab's impact on the rates of chronic GVHD and survival.

Single-arm studies have shown excellent survival outcomes with R-RIC in B cell NHL \[[@CR4], [@CR8], [@CR21]\]. Additional file [1](#MOESM1){ref-type="media"}: Table S7 summarizes the studies that looked at the addition of rituximab to RIC backbone in an effort to improve the outcomes. The current study is the first multicenter validation of these results, wherein there was a significant improvement in PFS in R-RIC group compared to the nonR-RIC group. Of note, in our study, the OS benefit emerged in the subset analysis excluding Flu/Bu patients. The fact that Flu/Bu was consistently associated with the lowest risk of NRM and improved PFS and OS (Additional file [1](#MOESM1){ref-type="media"}: Table S2) and that only 5% of Flu/Bu patients got R-RIC in our study prompted us to perform a subgroup multivariate analysis after excluding this conditioning approach. Whether the survival benefit that emerged in the non-Flu/Bu type R-RIC regimens also exists for Flu/Bu-based regimens requires further investigation.

In the recently reported BMT CTN 0701 study, OS was significantly better among patients who achieved a higher serum concentration of rituximab versus those with a lower serum concentration at day 28 \[[@CR8]\]. The association between rituximab dose and serum rituximab concentration is well known \[[@CR22]\]. In line with the observations made in BMT CTN 0701, in the current analysis, we observed that the patients who received a higher cumulative rituximab dose (a possible surrogate for higher serum concentrations) had better OS. We advise caution in interpreting the data of reduced mortality and NRM with higher cumulative rituximab dose in our study, given the small sample size (*n* = 45), the observed wide confidence intervals, and the non-significant overall *p* value of the model (Table [5](#Tab5){ref-type="table"}). Limited data suggest that rituximab in conditioning or its early application post allo-HCT might be associated with prolonged life-threatening cytopenias \[[@CR23]\]. In our study, rituximab use was not associated with delayed neutrophil recovery or fatal infections. Mortality due to GVHD was also comparable between the two groups. Four percent of deaths in the nonR-RIC group were due to GVHD as opposed to 6% in the R-RIC group (Additional file [1](#MOESM1){ref-type="media"}: Table S6).

Unfortunately, one of the limitations of the registry analysis is that we only capture the cumulative rituximab dose (at conditioning) and do not capture the exact dosing schedule. Additionally, only a small number of patients (*n* = 36) received post-transplant rituximab, thereby limiting the ability to assess the impact of post-transplant rituximab on the outcomes.

Conclusions {#Sec22}
===========

Our analysis is the largest comparative study evaluating outcomes of R-RIC versus nonR-RIC in B cell NHL patients. Although there was an increase in the risk of grade II--IV acute GVHD with R-RIC regimens, there was no increase in the risk of grade III--IV acute GVHD or chronic GVHD. There was a significant improvement in PFS with R-RIC allo-HCT in our study. Survival benefit was noted in the R-RIC group after exclusion of Flu/Bu conditioning regimen. Additionally, higher cumulative rituximab dose was associated with significantly improved survival. In the absence of randomized data, our results suggest that R-RIC should be considered as the preferred conditioning regimen for B cell lymphomas. Our encouraging data warrants confirmation in a randomized trial setting.
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Allo-HCT

:   Allogeneic hematopoietic cell transplantation

B-NHL

:   B cell non-Hodgkin lymphoma

CNI

:   Calcineurin inhibitor

CR

:   Complete remission

CRF

:   Comprehensive Report Form

DLBCL

:   Diffuse large B cell lymphoma

FCR

:   Fludarabine, cyclophosphamide, and rituximab

FL

:   Follicular lymphoma

Flu/Bu

:   Fludarabine, busulfan

GVHD

:   Graft-versus-host disease

MCL

:   Mantle cell lymphoma

MZL

:   Marginal zone lymphoma

NonR-RIC

:   Rituximab-containing reduced-intensity conditioning

NRM

:   Non-relapse mortality

OS

:   Overall survival

PFS

:   Progression-free survival

PR

:   Partial remission

RR

:   Relative risk

R-RIC

:   Rituximab-containing reduced-intensity conditioning

TBI

:   Total body irradiation

TED

:   Transplant Essential Data
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